Before founding 5AM Ventures in 2002, Andy was a Principal at Bay City Capital (BCC) where he led many of the firm's investment and merchant banking activities for such companies as Cubist, Lombard Odier, Metabolex, PTC Therapeutics, Symyx, and Syrrx.
Prior to BCC, Andy was Vice President of Business Development at Digital Gene Technologies and a Vice President in the life science investment banking group of Montgomery Securities.
He serves on the Board of Directors of Aravis Venture I, Genospectra, Ikaria, Ilypsa, Miikana Therapeutics, Smart Drug Systems, and the Cincinnati Children's Hospital Technology Validation Advisory Board.
Andy received a BS with honors in Genetics and Ethics from Davidson College. Andy is based in the San Francisco office.